{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-219180","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.498463+00:00","generated_at":"2026-05-31T04:39:45.710217+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared","bullets":["Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.","Statistically significant segregation of responders vs OncoSignature- arm (p=0.009); all responding patients still on therapy; mDoR not yet reached (~6 months).","Endometrial cancer anticipated as first potential accelerated approval opportunity for ACR-368.","FDA cleared IND for ACR-2316 (dual WEE1/PKMYT1 inhibitor); clinical sites activated; first-in-human dosing expected Q4 2024.","Cash of $220.4M (June 30, 2024) expected to fund operations into H2 2026; guidance reiterated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-219180","json":"https://secwatch.observer/filing/0001193125-24-219180.json","markdown":"https://secwatch.observer/filing/0001193125-24-219180.md","text":"https://secwatch.observer/filing/0001193125-24-219180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/0001193125-24-219180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/d355136d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:39:45.710217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}